Tailoring Obesity Treatment Trial

What this study is testing ClinicalTrials.gov NCT06619015 ↗

Description as written by the study sponsor.

The two main aims of this clinical study is; 1. To investigate if the results from a series of physiological tests and questionnaires prior to treatment, can be used to predict the treatment response to obesity medication 2. To investigate the effect of combining semaglutide and pramlintide on various aspects of appetite, food preference and eating habits. The study is planed as a 26 week, double blinded, randomized, placebo controlled trial. The goal is to include N=40. They will all receive weekly semaglutide injections. After 24 weeks they will be randomized to receive either an amylin analog (pramlintide) or placebo as a continuous infusion for two weeks, in addition to weekly semaglutide. The results from this study will contribute to identifying possible predictors of treatment response, enabling optimal individualized medical weight loss treatment. As well as providing knowledge on the complex interplay between incretin hormones and their effects on appetite and eating habits.

Treatments tested

• Pramlintide Acetate 1 MG/ML also known as Symlin Drug

  Symlin (R) (Pramlintide acetate) 1000mcg/ml, will be administered as a continuous infusion at a rate of 15mcg/hour, equivalent to the daily recommended maximum dosage of 360mcg/day.

• Semaglutide Pen Injector also known as Wegovy Drug

  Semaglutide from 0,25mg/week to 2,4mg/week

• Sodium Chloride 0.9% Inj also known as isotonic saline solution Drug

  Placebo